dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· December 16, 2025

XRP Lost Over 45% Since July Peak: Can $1B ETF Momentum Reverse the Slide?

View original at finance.yahoo.com
XRP Lost Over 45% Since July Peak: Can $1B ETF Momentum Reverse the Slide? Tamisclao / Shutterstock.com Quick Read XRP dropped from $3.66 in July 2025 to around $2.00 by December 2025, losing over 45% as 37% of holders sit on unrealized losses U.S…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Technical forecasts suggest a break under $2.00 may target $1.90-1.95 initially, with deeper slides to $1.50 possible if the downtrend intensifies

    80% confidence

  • If XRP ETF inflows continue at current trends, the float may shrink by another 2-3% by Q1 2026

    80% confidence

  • The SEC's approval regime and court rulings characterizing XRP as a commodity made it a compliance-friendly token for advisors

    80% confidence

  • XRP could approach its old $3.66 high by late 2026, driven by shrinking exchange float and steady institutional accumulation

    80% confidence

  • Analysts argue these institutional XRP ETF inflows create a structural bid under XRP

    80% confidence

  • Approximately 37% of XRP's circulating supply sits in unrealized loss

    80% confidence

  • Since mid-November, U.S. XRP ETF inflows amassed over $1 billion and absorbed nearly 1% of XRP's circulating supply

    80% confidence

  • This supply squeeze mirrors what happened to Bitcoin after ETF approval—shrinking float, then rallies

    80% confidence

Data points we hold from this source

XRP · unrealized loss percentage37 percent
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,997
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,997 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
XRP Lost Over 45% Since July Peak: Can $1B ETF Momentum Reverse the Slide?: Source | Via News | fr.via.news